Welcome to our dedicated page for ARGAN SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. SEC filings document the company’s operating results, material events and governance as a NYSE-listed construction services issuer. Recent 8-K filings report quarterly and fiscal financial results, cash dividends, share repurchase program actions, and engineering, procurement and construction contract developments involving Gemma Power Systems and power-generation projects.
Proxy materials cover board elections, executive compensation, equity awards, shareholder voting matters and related governance disclosures. The filings also identify Argan’s common stock registration and formal event reporting for capital allocation and project-backlog developments.
ARGAN INC director Cynthia Flanders reported an open-market sale of 2,596 shares of the company’s common stock. The trade took place on June 15, 2026 at a price of $666.31 per share. Following this transaction, she directly holds 23,144 common shares.
ARGAN INC president and CEO David Hibbert Watson reported a mix of stock sales and option exercises in company shares. On June 15, 2026, he sold 9,993 common shares in open-market trades at an average price of $651.22 per share. On June 16, 2026, he sold a further 1,880 shares at an average price of $707.35 per share and exercised stock options covering a total of 3,333 shares at exercise prices of $39.47, $61.22, and $148.72 per share using the net settle method. The filing reflects both profit-taking sales and increased direct ownership from option exercises.
ARGAN INC director-associated entity sells shares in an open-market transaction. On June 12, 2026, an entity associated with director William F. Griffin Jr., identified as William F Griffin Jr GRAT II dtd Oct 6, 2025, sold 50,000 shares of Argan common stock at an average price of $643.46 per share. Following this sale, the GRAT continued to hold 90,976 Argan shares indirectly for Griffin.
AGX files a notice of proposed sale of 4,728 shares of Common Stock related to the exercise of options under a registered plan dated 06/16/2026. The filing lists prior sales by Peter W. Getsinger of 3,000 shares on 04/29/2026 and 2,581 shares on 04/02/2026, with cash consideration noted for the exercise.
David Watson submitted a notice under Rule 144 relating to proposed sales of Common Stock of AGX. The filing lists a planned equity grant/exercise of 1,880 shares on 06/16/2026 and reports shares sold in the past three months of 9,993 shares on 06/15/2026 and 19,310 shares on 04/17/2026.
AGX submitted a Form 144 notice for proposed sales of Common Stock. The filing lists multiple proposed dispositions tied to restricted stock issuances and an option exercise on 06/15/2026, with specific lot sizes shown for earlier issuance dates. The securities are listed as Common Stock on NYSE.
ARGAN INC director Cynthia Flanders reported several equity-related moves involving the company’s common stock and restricted stock units. She exercised derivative securities to acquire 533 shares of common stock, then made a bona fide gift of 1,000 common shares, leaving her with 25,207 shares held directly.
Flanders’ compensation also included equity awards tied to future service. She was granted time-based restricted stock units covering 189 shares of common stock, which will fully vest on June 10, 2027 or on the date of the 2027 Annual Meeting of Stockholders, whichever occurs first. She also converted 530 previously awarded time-based restricted stock units into common shares, and now holds 834 time-based restricted stock units following these transactions.
ARGAN INC director Karen Sweeney reported routine equity compensation transactions. On June 10, 2026, she exercised awards to acquire 533 shares of common stock, bringing her direct common stock holdings to 1,848 shares. She also converted previously granted time-based restricted stock units (TRSUs) into 530 shares of common stock that became issuable under a one-year vesting schedule tied to TRSUs awarded on June 17, 2025. In addition, she received a new grant of 189 TRSUs, each linked to one share of common stock, which will vest in full on June 10, 2027 or on the date of the 2027 Annual Meeting of Stockholders, whichever occurs first. No sales or dispositions were reported in this filing.
Leimkuhler William F. reported acquisition or exercise transactions in this Form 4 filing.
ARGAN INC director William F. Leimkuhler reported routine equity compensation activity. On June 10, 2026, 530 Time-Based Restricted Stock Units (TRSUs) vested into common shares under a one-year schedule from a June 17, 2025 award, and he was granted a new award of 189 TRSUs that will fully vest on June 10, 2027 or at the 2027 Annual Meeting of Stockholders, whichever comes first. Following these transactions, he directly holds 37,028 shares of common stock, 1,023 TRSUs, and indirectly holds 500 shares in each of two trusts for which he serves as trustee.